a) CDTi priority areas
   Ivermectin treatment

b) Risks – SAEs in potential
   LF and Loa loa >40% areas

c) Benefits – ivermectin in
   low–average LF areas

---

d) STH recommended treatment
   – once yearly treatment
   – twice yearly
   – mass treatment unnecessary/undefined

f) Benefits – large areas overlapping
   with ivermectin treatment

---

g) Bednet / ITN ownership
   – <35%
   – >35%  

h) Risks - Low % of nets / ITNs
   – in potential LF and Loa loa >40% areas

i) Benefits – higher % net/ITNs
   – in high prevalence LF areas

---

Figure 4.